Clinical Trials
2
Active:1
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
Phase 1
Active, not recruiting
- Conditions
- SLE (Systemic Lupus)AutoimmuneSystemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Cugene Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05866861
- Locations
- 🇺🇸
Site 1001, Anniston, Alabama, United States
🇺🇸Site 1011, La Jolla, California, United States
🇺🇸Site 1002, Clearwater, Florida, United States
A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Cugene Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05328557
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
News
No news found